October 19, 2019 – Paragon Biosciences CEO Jeff Aronin spoke with Crain’s Chicago Business on his role in the company, his vision for Paragon, and his mission to bring treatments to patients suffering from rare, genetic, debilitating diseases that too few companies focus on.
In an exclusive interview, Jeff shared Paragon’s announcement on the completion of a new capital investment of $71.8 million in support of portfolio company Castle Creek. Paragon organized the $71.8 million investment from respected firms, Fidelity Management & Research Company and Valor Equity Partners, for late-stage development of treatments for rare genetic dermatologic diseases.
During his interview, Jeff shared that “Paragon was designed with a mission to help these patients who have no treatment options or poor treatment options. We identify a disease, develop science to treat that disease, and build companies” like Castle Creek that produce therapies for patients with rare conditions.
Read the full story here